Another India drug maker ‘Wockhardt’ banned in U.S.
The U.S. Food and Drug Administration has imposed an import ban on Indian drug manufacturer Wockhardt Ltd. after one of the company’s plants at Aurangabad in Maharashtra failed an FDA safety inspection.
The import ban only applies to drugs manufactured at company’s factories in Aurangabad. As per FDA the plant didn’t meet good manufacturing practices. The ban could cause to a revenue loss of $100 million for the company this fiscal year.
Recently an Indian generic drug maker company Ranbaxy Laboratories Ltd. agreed to pay $500 million to settle suits against company’s poor management and manufacturing practices and distribution of adulterated drugs in the U.S.